nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

19.04.2024 | Oculoplastics and Orbit

Teprotumumab improves light sensitivity in patients with thyroid eye disease

verfasst von: Emanuil Parunakian, Shoaib Ugradar, Joseph Tolentino, Emil Malkhasyan, Pershanjit Raika, Joseph Ghaly, Chirag Bisht, Raymond S Douglas

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology

Einloggen, um Zugang zu erhalten

Abstract

Background

Teprotumumab, a novel IGF-1R antibody, has been shown to significantly reduce the signs of acute and chronic Thyroid Eye Disease (TED). Light sensitivity is a reported symptom in patients with TED. There is a lack of a prospective study that has explored the effects on light sensitivity in a large cohort of patients with acute and chronic TED following treatment with teprotumumab.

Methods

Consecutive patients who were diagnosed with TED and reported light sensitivity at baseline were considered for study eligibility. All patients had measurements of Visual Light Sensitivity Questionnaire-8 (VLSQ-8), proptosis, clinical activity score (CAS), and MRD1 (distance between the upper eyelid margin and corneal reflex, mm) and MRD2 (distance between the lower eyelid margin and corneal reflex, mm) before and after treatment.

Results

Ninety patients (41 acute, 49 chronic) met the inclusion criteria. The mean (SD) age was 47.3 (14.3). Eighty-six (95.6%) patients completed all 8 infusions. There was a significant reduction in the total score and across all categories of the VLSQ-8 (p < 0.01 for all). Seventy-two (80%) patients had a clinically significant improvement (≥2 reduction) in at least one category. There was no significant difference in the total VLSQ-8 score between the acute and chronic group (p = 0.8).

Conclusion

Teprotumumab improves light sensitivity in patients with acute and chronic TED.

The results of this study highlight that the improvements in light sensitivity following treatment are not directly related to the mechanical changes in TED, suggesting another underlying mechanism is potentially involved.

Tsui S, Naik V, Hoa N et al (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in graves’ disease. J Immunol 181:4397–4405. https://doi.org/10.4049/jimmunol.181.6.4397CrossRefPubMed

Ugradar S, Shi L, Wang Y et al (2021) Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye 35:2607–2612. https://doi.org/10.1038/s41433-020-01297-wCrossRefPubMed

Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated Ophthalmopathy. N Engl J Med 376:1748–1761. https://doi.org/10.1056/NEJMoa1614949CrossRefPubMedPubMedCentral

Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341–352. https://doi.org/10.1056/NEJMOA1910434CrossRefPubMed

Ugradar S, Kang J, Kossler AL et al (2022) Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond) 36:1553–1559. https://doi.org/10.1038/s41433-021-01593-zCrossRefPubMed

Douglas RS, Couch S, Wester ST et al (2023) Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab 109:25–35. https://doi.org/10.1210/clinem/dgad637

Cockerham KP, Padnick-Silver L, Stuertz N et al (2021) Quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmol Ther 10:975–987. https://doi.org/10.1007/s40123-021-00385-8CrossRefPubMedPubMedCentral

Ugradar S, Zimmerman E, Parunakian E et al (2023) Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. Clin Experiment Ophthalmol 51:339–348. https://doi.org/10.1111/ceo.14208CrossRefPubMed

Verriotto JD, Gonzalez A, Aguilar MC et al (2017) New methods for quantification of visual photosensitivity threshold and symptoms. Transl Vis Sci Technol 6:18. https://doi.org/10.1167/tvst.6.4.18CrossRefPubMedPubMedCentral

10.

Venkateswaran N, Hwang J, Rong AJ et al (2020) Periorbital botulinum toxin a improves photophobia and sensations of dryness in patients without migraine: case series of four patients. Am J Ophthalmol Case Rep 19:100809. https://doi.org/10.1016/j.ajoc.2020.100809CrossRefPubMedPubMedCentral

11.

Mourits MP, Koornneef L, Wiersinga WM et al (1989) Clinical criteria for the assessment of disease activity in graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 73:639–644. https://doi.org/10.1136/bjo.73.8.639CrossRefPubMedPubMedCentral

12.

Rüfer F, Schröder A, Erb C (2005) White-to-white corneal diameter. Cornea 24:259–261. https://doi.org/10.1097/01.ico.0000148312.01805.53CrossRefPubMed

13.

Villani E, Viola F, Sala R et al (2010) Corneal involvement in graves’ Orbitopathy: an in vivo confocal study. Investigative Opthalmology & Visual Science 51:4574. https://doi.org/10.1167/iovs.10-5380CrossRef

14.

Wu L-Q, Cheng J-W, Cai J-P et al (2016) Observation of corneal Langerhans cells by in vivo confocal microscopy in thyroid-associated Ophthalmopathy. Curr Eye Res 41:927–932. https://doi.org/10.3109/02713683.2015.1133833CrossRefPubMed

15.

Oklar M, Yazicioglu T, Ozen MC et al (2023) Evaluation of corneal endothelium and correlation with disease severity in patients with graves’ ophthalmopathy: a specular microscopy-based study. Photodiagn Photodyn Ther 42:103592. https://doi.org/10.1016/j.pdpdt.2023.103592CrossRef

16.

Wu Y-C, Zhu M, Robertson DM (2012) Novel nuclear localization and potential function of insulin-like growth Factor-1 receptor/insulin receptor hybrid in corneal epithelial cells. PLoS One 7:e42483. https://doi.org/10.1371/journal.pone.0042483CrossRefPubMedPubMedCentral

17.

Nakamura M, Chikama T-I, Nishida T (2000) Characterization of insulin-like growth Factor-1 receptors in rabbit corneal epithelial cells. Exp Eye Res 70:199–204. https://doi.org/10.1006/exer.1999.0775CrossRefPubMed

18.

Rocha EM, Cunba DA, Carneiro EM et al (2002) Identification of insulin in the tear film and insulin receptor and IGF-1 receptor on the human ocular surface. Invest Ophthalmol Vis Sci 43

19.

Titone R, Zhu M, Robertson DM (2018) Insulin mediates de novo nuclear accumulation of the IGF-1/insulin hybrid receptor in corneal epithelial cells. Sci Rep 8:4378. https://doi.org/10.1038/s41598-018-21031-7CrossRefPubMedPubMedCentral

20.

Robertson DM, Zhu M, Wu Y-C (2012) Cellular distribution of the IGF-1R in corneal epithelial cells. Exp Eye Res 94:179–186. https://doi.org/10.1016/j.exer.2011.12.006CrossRefPubMed

Titel: Teprotumumab improves light sensitivity in patients with thyroid eye disease
verfasst von: Emanuil Parunakian
Shoaib Ugradar
Joseph Tolentino
Emil Malkhasyan
Pershanjit Raika
Joseph Ghaly
Chirag Bisht
Raymond S Douglas
Publikationsdatum: 19.04.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-024-06491-0

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Teprotumumab improves light sensitivity in patients with thyroid eye disease

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde